Black Diamond Therapeutics (BDTX) Common Equity: 2018-2021
Historic Common Equity for Black Diamond Therapeutics (BDTX) over the last 3 years, with Sep 2021 value amounting to $218.9 million.
- Black Diamond Therapeutics' Common Equity fell 33.11% to $218.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $218.9 million, marking a year-over-year decrease of 33.11%. This contributed to the annual value of $307.8 million for FY2020, which is 752.62% up from last year.
- Per Black Diamond Therapeutics' latest filing, its Common Equity stood at $218.9 million for Q3 2021, which was down 12.78% from $251.0 million recorded in Q2 2021.
- Black Diamond Therapeutics' Common Equity's 5-year high stood at $355.3 million during Q1 2020, with a 5-year trough of -$47.2 million in Q4 2019.
- Its 3-year average for Common Equity is $177.0 million, with a median of $251.0 million in 2021.
- Its Common Equity has fluctuated over the past 5 years, first slumped by 203.42% in 2019, then spiked by 1,942.76% in 2020.
- Over the past 4 years, Black Diamond Therapeutics' Common Equity (Quarterly) stood at -$15.5 million in 2018, then crashed by 203.42% to -$47.2 million in 2019, then spiked by 752.62% to $307.8 million in 2020, then slumped by 33.11% to $218.9 million in 2021.
- Its last three reported values are $218.9 million in Q3 2021, $251.0 million for Q2 2021, and $280.8 million during Q1 2021.